Versant & MPM Back Synthetic Lethality Newco With $68M

Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.

Synthetic lethality, a term borrowed by cancer researchers from classical genetics to describe when a cancer mutation and a drug combine to trigger a tumor cell’s death, underpins the creation of biotech newco Repare Therapeutics Inc. Raising $68 million in a series A round, co-led by venture capitalists Versant Ventures and MPM Capital, Repare intends to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers. Other investors in the syndicate included FTQ, Celgene Corp.’s Celgene Switzerland LLC affiliate and BDC Ventures.

“The fields of synthetic lethality and DNA repair have a rich, 20‐year history and are poised to deliver impactful new...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.